Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

• DOI: 10.1016/j.euf.2023.06.006
• Publication Date: 2023-07-06T19:48:06Z
• Authors: Max Kates; Xiangying Chu; Noah Hahn; Eugene Pietzak; Angela Smith; Daniel H. Shevrin; Paul Crispen; Stephen B. Williams; Siamak Daneshmand; Vignesh T. Packiam; Sima Porten; Mary E. Westerman; Lynne I. Wagner; Michael Carducci
• Keywords: Administration, Intravesical; Urinary Bladder Neoplasms; Clinical Trials, Phase III as Topic; BCG Vaccine; Humans; Docetaxel; Gemcitabine; Non-Muscle Invasive Bladder Neoplasms; 3. Good health; Randomized Controlled Trials as Topic

EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.